Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Drug Treatment Reduces Chronic Pain Following Shingles

Published: Friday, February 07, 2014
Last Updated: Friday, February 07, 2014
Bookmark and Share
New drug EMA401 reduce pain and did not cause any serious side effects.

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

The researchers hope that the drug might also be effective against other causes of chronic neuropathic pain, such as diabetes, HIV, nerve injury and cancer chemotherapy, as it targets a mechanism that is not targeted by any existing therapies and has fewer side effects.

Drugs available now have limited success at treating neuropathic pain and often have unpleasant or disabling side effects.

It is estimated that around 190,000 people in the UK get shingles every year, most of them aged over 50. It is caused when a dormant viral infection of a nerve is reactivated, resulting in a painful rash. In most cases, the shingles rash lasts a few weeks, but in some cases the permanent nerve damage caused by the virus results in a chronic neuropathic pain called post-herpetic neuralgia. Around one in 10 people with shingles experiences post-herpetic neuralgia and, once established, it usually causes life-long suffering.

In a study involving 183 patients with post-herpetic neuralgia in six countries, the new drug EMA401 was found to reduce pain and did not cause any serious side effects.

Lead author Professor Andrew Rice, from the Department of Surgery and Cancer at Imperial College London, said: "Conventional painkillers don't tend to help people with severe chronic neuropathic pain and most available treatments have modest efficacy and/or are limited by side effects. We are therefore keen to find new ways of providing these people with some relief.

"A positive trial like this in such a challenging condition as post-herpetic neuralgia, for a drug that acts in a new way, is unusual and very exciting. We hope that the new drug will ultimately offer hope for patients who aren't helped by current treatments."

The study, a phase 2 trial, compared EMA401 with a placebo, with participants taking two pills a day for four weeks. Fifty-eight per cent of participants taking the drug found it effective, reducing pain by at least 30 per cent.

Spinifex Pharmaceuticals, which owns the drug, now plans to conduct a larger trial, possibly testing higher doses of the drug for longer periods of time.

"We are looking forward to seeing how EMA401 performs in a larger trial in people with post-herpetic neuralgia, where we will explore higher doses, and in trials where we will analyze its efficacy in other chronic pain conditions. Identifying the characteristics of the patients who do get good pain relief from EMA401 will also be an important avenue for research," added Professor Rice.

Tom McCarthy, CEO of Spinifex Pharmaceuticals, said: "There is a clear need for new treatments that bring patients pain relief with fewer side effects. In addition to post-herpetic neuralgia, we see broad potential for EMA401 to treat a range of chronic painful conditions such as pain due to osteoarthritis and diabetes. We look forward to delivering on the further development of EMA401."

Spinifex's clinical program for EMA401 includes a clinical trial in the treatment of neuropathic pain in patients after cancer chemotherapy, which is being conducted by Professor Praveen Anand at Imperial College London. Professor Anand's group also conducted key clinical tissue research which led up to the trials.

Professor Rice works with patients with neuropathic pain at Chelsea and Westminster Hospital, where he is a Consultant in Pain Medicine. He has worked with Spinifex through Imperial Consultants on the pre-clinical development of the new drug since 2005.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protein ‘Map’ Could Lead to Potent New Cancer Drugs
Findings will help scientists to design drugs that could target NMT enzyme.
Saturday, September 27, 2014
Malaria Drug Target Raises Hopes for New Treatments
Scientists identify way to stop malaria parasites from multiplying.
Thursday, December 26, 2013
New Drugs Hope for Dangerous Yeast Infections
Researchers from ICL have now found out yeast cells identify and attach to human tissue in order to colonize it and cause an infection.
Tuesday, September 06, 2011
New Chief Financial Officer Appointed at Imperial College London
ICL announces Muir Sanderson as new Chief Financial Officer.
Wednesday, August 10, 2011
Scientists Find New Drug Target in Breast Cancer
Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments.
Monday, May 23, 2011
Switch that Enables Salmonella to Sabotage Host Cells Revealed in new Study
A new switch that enables Salmonella bacteria to sabotage host cells is revealed in a study published in the journal Science.
Friday, April 23, 2010
Blood Clotting Finding may Lead to New Treatments
Researchers find that a key protein that causes the blood to clot is produced by blood vessels in the lungs and not just the liver.
Thursday, February 11, 2010
Drug Shrinks Lung Cancer Tumors in Mice
A potential new drug for lung cancer has eliminated tumors in 50% of mice in a new study published in the journal Cancer Research.
Tuesday, November 10, 2009
Drug Shrinks Lung Cancer Tumours in Mice
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research.
Monday, November 09, 2009
Urine Samples could be Used to Predict Responses to Drugs, Say Researchers
Researchers show possibility to predict how different individuals would deal with one drug by looking at metabolites in their urine.
Tuesday, August 11, 2009
Award for Pioneering Stem Cell Research to Mend Broken Bones
New funding could lead to the development of new and better treatments for broken bones and other orthopaedic problems.
Wednesday, May 27, 2009
On-the-spot DNA Analysis to Test Tolerance to Prescription Drugs Gets Closer
A handheld device to predict whether patients will respond adversely to medication is one step closer to the market.
Tuesday, February 17, 2009
Chemical Signature of Manic Depression Discovered by Scientists
People with manic depression have a distinct chemical signature in their brains, according to a new study.
Thursday, February 07, 2008
Targeting Gut Bugs could Revolutionize Future Drugs, say Researchers
Revolutionary new ways to tackle certain diseases could be provided by creating drugs which change the bugs in people's guts.
Monday, February 04, 2008
Scientists Capture the Speediest Ever Motion in a Molecule
The finding gives an in-depth understanding of how molecules behave in chemical processes.
Friday, March 03, 2006
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!